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Abstract: Exosomes are secreted cellular vesicles that
can induce specific CD4
+ T cell responses in vivo when
they interact with competent antigen-presenting cells
like mature dendritic cells (mDCs). The Trojan exosome
hypothesis proposes that retroviruses can take advan-
tage of the cell-encoded intercellular vesicle traffic and
exosome exchange pathway, moving between cells in
the absence of fusion events in search of adequate target
cells. Here, we discuss recent data supporting this
hypothesis, which further explains how DCs can capture
and internalize retroviruses like HIV-1 in the absence of
fusion events, leading to the productive infection of
interacting CD4
+ T cells and contributing to viral spread
through a mechanism known as trans-infection. We
suggest that HIV-1 can exploit an exosome antigen-
dissemination pathway intrinsic to mDCs, allowing viral
internalization and final trans-infection of CD4
+ T cells. In
contrast to previous reports that focus on the ability of
immature DCs to capture HIV in the mucosa, this review
emphasizes the outstanding role that mature DCs
could have promoting trans-infection in the lymph node,
underscoring a new potential viral dissemination
pathway.
Introduction
Dendritic cells (DCs) scattered throughout the peripheral tissues
act like sentinels and recognize a wide range of microorganisms. At
this stage, DCs display an immature phenotype. When pathogen
invasion takes place, immature DCs (iDCs) can capture microor-
ganisms via endocytic surveillance receptors, resulting in the
classical intracellular lytic pathway that permits processing of
antigenic peptides [1]. The signaling through receptors or the
detection of proinflammatory cytokines prompts iDC activation
and migration from the periphery towards the secondary
lymphoid organs. Concurrently, co-stimulatory molecules are
expressed in the cell membrane, preparing DCs for competent T
cell priming. In the T cell areas of the lymph nodes, fully mature
DCs (mDCs) present pathogen-derived epitopes to CD4
+ To r
CD8
+ T lymphocytes. This way, DCs orchestrate immune
responses to invading pathogens and have a pivotal role during
infections [2].
However, viruses, including the human immunodeficiency virus
(HIV), have evolved different strategies to evade DC antiviral
activity. Indeed, it has been known for years that DCs exposed to
HIV-1 transmit a vigorous cytopathic infection to CD4
+ T cells
[3]. Although the frequency of HIV-1-infected DCs is often 10- to
100-fold lower than that of CD4
+ T cells [4], DCs do not need to
be productively infected to transmit the virus and spread it in an
infectious form [5], which is in contrast to other HIV-1 target cells
such as CD4
+ T cells or macrophages. Notably, separate pathways
mediate the productive infection of DCs and their ability to
capture and internalize HIV-1 in the absence of viral fusion [6].
The latter mechanism involves binding and uptake of HIV-1,
traffic of internalized virus, and its final release, allowing transfer
to CD4
+ T cells, a process known as trans-infection [5,7].
Trans-infection has been related to the ability of C-type lectin
receptors like DC-SIGN expressed in certain DCs to tightly bind
to the HIV-1 surface envelope glycoprotein gp120 [8] and
endocytose viral particles [9]. The initial identification of DC-
SIGN as an HIV receptor permitting trans-infection of T cells led
to the ‘‘Trojan horse’’ hypothesis, which relates the preliminary
establishment of HIV-1 infection to the ability of iDCs to capture
the virus via DC-SIGN in the peripheral tissue and then migrate to
the lymph nodes, where HIV-1 transferred to CD4
+ T cells could
easily start the spread of infection [5,7,10].
Knowing the antigen-presenting capabilities of DCs, one would
expect that after HIV interaction with surveillance receptors like
DC-SIGN, endocytosed virus would end up in classical lysosomic
pathways (Figure 1), where viral antigens are degraded and
presented in MHC-II molecules to CD4
+ T cells [11,12].
Furthermore, part of the internalized virus could also gain access
to the cytoplasm and be processed throughout the proteasome,
finally being crosspresented in MHC-I molecules to CD8
+ T cells
[13,14]. However, in the specific case of HIV interaction with
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escapes these degradation routes and is maintained in endosomal
acidic compartments, retaining viral infectivity for the long periods
required to promote efficient HIV-1 transfer to CD4
+ T cells [5,9].
Despite this preliminary model of viral retention, recent studies
have demonstrated that iDCs show rapid degradation of captured
viral particles, which do not last more than 24 hours before being
processed [14–17]. These studies suggest a two-phase mechanism
of viral transmission mediated by iDCs: one restricted to a short
period through the trans-infection process, and a later one due to a
long-term transfer of de novo viral particles produced after iDC
infection [15,16,18].
Trojan Horses and HIV Transmission: Mature DCs
Win the Race
Several results ([17,19–21], reviewed in [22]), indicate that iDCs
have reduced trans-infection ability. Conversely, mDCs are much
less vulnerable to viral fusion events and productive HIV infection
than iDCs [23,24], while displaying a greater ability to capture
incoming virions [17,21,25], retain them in an infectious form,
and transmit them to target T cells through trans-infection [17,19–
21]. The location of internalized virions is dramatically different in
immature and mature DCs [25]. Strikingly, the poorly macro-
pinocytic mDCs [2,26,27] sequester significantly more whole,
structurally intact virions into large vesicles within the cells,
whereas the endocytically active iDCs not only retain fewer
internalized virions, but also locate them closer to the cell
periphery [25]. This internalization view has been previously
challenged, suggesting that cell-surface-bound HIV is the
predominant pathway for viral transmission mediated by DCs
[28]. However, a recent report on this topic reconciles these two
models by demonstrating that HIV resides in an invaginated
domain within DCs that is both contiguous with the plasma
membrane and distinct from classical endocytic vesicles [29].
Collectively, these results favor a model in which both direct
infection and trans-infection abilities coexist to a different extent in





















Figure 1. Antigen presentation and trans-infection of a CD4
+ T cell mediated by a DC. Viral binding to distinct cellular receptors allows viral
endocytosis via a non-fusogenic mechanism (1). The virus is retained in the multivesicular body compartment (MVB), where it is enriched in
tetraspanins such as CD81 and CD63. Part of the virus is degraded in the lysosomes (2), and viral antigens are presented via MHC-II to the T cell
receptor (TCR) of CD4
+ T cells (3) through the formation of an immunological synapse. If an endocytosed virus gains access to the cytoplasm of the
DC, it can be processed by the proteasome and crosspresented via MHC-I to CD8
+ T cells (4). Viral transmission takes place when part of the virus
evades classical degradation pathways. MVB recycles back and fuses with the plasma membrane, allowing the liberation of entrapped virus and the
productive infection of DC-interacting CD4
+ T cells (5), a mechanism known as trans-infection. The contact area between an uninfected DC bearing
HIV infectious particles and a CD4
+ T cell is termed the infectious synapse.
doi:10.1371/journal.ppat.1000740.g001
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viral fusion events [24] and productive infection [23]. Under these
circumstances, iDCs would preferentially transmit de novo
synthesized virus upon productive infection [15], and the mDC-
enhanced trans-infection ability would play a key role in the lymph
nodes, mediating viral transmission to new target CD4
+ T cells
(Figure 2).
Given the unique capability of mDCs to promote HIV-1
infection of CD4
+ T cells in vitro, we hypothesize that in vivo,
mDC trans-infection could augment viral dissemination in the
lymphoid tissue and significantly contribute to HIV disease
progression. mDCs have a greater ability to stimulate CD4
+ T
cell proliferation than iDCs [30,31]. Accordingly, mDCs present-
ing viral antigens could activate HIV-specific naı ¨ve CD4
+ T cells
in the course of their first encounters in the lymph node. As a
result, HIV-specific naı ¨ve CD4
+ T cells would undergo several
rounds of division during their initial expansion and differentiation
into effector CD4
+ T cells, becoming highly susceptible to actual
HIV infection, as has been previously demonstrated [32]. Notably,
the viral dissemination that mDCs can potentially mediate in vivo
is enormous: T cells approach mDCs randomly and make
exploratory contacts that last only minutes, enabling DCs to
contact many T cells per hour [33]. Thus, since viral transmission
through trans-infection does not rely on antigen presentation, many
CD4
+ T cells could be exposed to mDC virus; however, only after
antigen presentation would naı ¨ve CD4
+ T cells be activated and
their subsequent proliferation render these cells more susceptible
to HIV infection.
Once infected, these activated CD4
+ T cells are known to have
short half-lives in vivo, lasting fewer than two days [34]. Therefore,
under rapid T cell turnover, DCs could be indispensable to
permitting continuous infection of new CD4
+ T cells [35]. Recently,
ithasalsobeensuggested thatsimultaneouspriming and infectionof
T cells by DCs is the main driving force behind the early infection
dynamics, when activated CD4
+ T cell numbers are low [36].
In vivo, the contribution of mDCs to HIV spread might be also
supported by the levels of circulating lipopolysaccharide (LPS),
which are significantly augmented in chronically HIV-infected
individuals, due to the increased translocation of bacteria from the
intestinal lumen early after primo infection [37]. The bacterial
components released could stimulate DCs systemically, contribut-
ing to their maturation and therefore enhancing viral spread while
creating the pro-inflammatory milieu associated with chronic HIV
infection. This hypothesis is further supported by another report
showing that in individuals with HIV-1 viremia, DCs from blood
have increased expression levels of co-stimulatory molecules (the
hallmark of maturation status) that only diminish when highly
active antiretroviral therapy suppresses the viral load [38].
Although the plasma LPS concentration found in HIV
+ patients
is lower than the one used to mature DCs in vitro [17,19–21,39], it
is conceivable that in vivo, higher amounts of LPS could
accumulate in the most compartmentalized areas of the mucosa
or in the adjacent tissues. Therefore, future experiments should
address whether the physiological amounts of LPS found in tissues
can trigger the same DC maturation status and viral transmission
efficacy described in different reports [17,19–21,39].
Figure 2. Proposed major roles of iDCs and mDCs during HIV disease progression. Productive infection of iDCs allows viral transmission in
the peripheral tissues, while mDC viral capture leads to trans-infection in the lymphoid tissues.
doi:10.1371/journal.ppat.1000740.g002
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strongly associated with the sexual transmission of HIV [40]. This
implies that the probability of a person acquiring HIV infection is
increased when there is a preexisting infection or inflammation of
the genital epithelium. Under these circumstances, it is quite likely
that mucosal inflammation arising from other sexually transmitted
pathogens could directly activate and mature DCs in vivo,
promoting HIV settlement and favoring the subsequent spread
of the viral infection. Interestingly, a recent report shows that in
vitro–activated CD34-derived Langerhans cells mediate the trans-
infection of HIV [39], suggesting a potential role for these mature
cells during the establishment of HIV infection.
Unfortunately, recent failures in HIV prophylactic vaccine trials
provide additional corroboration of the prominent role mDCs
could be playing during HIV infection in vivo. The STEP HIV
vaccine trial evaluated a replication-defective adenovirus type 5
(Ad5) vector, which is a weakened form of a common cold virus,
modified to carry HIV genes into the body to induce HIV-specific
immune responses. This clinical trial was recently stopped due to
the vaccine’s lack of efficacy and the 2-fold increase in the
incidence of HIV acquisition among vaccinated recipients with
increased Ad5-neutralizing antibody titers compared with placebo
recipients [41]. Of note, a recent report demonstrates that the Ad5
vector, with its neutralizing antiserum (present in people with prior
immunity), induced a more marked DC maturation than the
vector alone, as indicated by increased CD86 expression levels,
decreased endocytosis, and production of tumor necrosis factor
and type I interferons [42]. Furthermore, when the Ad5 vector
and the neutralizing antiserum were added to DCs pulsed with
HIV, significantly enhanced viral infection was observed in DC–T
cell co-cultures compared to controls lacking the neutralizing
antiserum. That is why these authors postulate that mDCs from
people with prior immunity to Ad5 virus might have activated
CD4
+ T cells in vivo, augmenting their susceptibility to HIV
infection [42].
Overall, these results highlight the functional relevance that DC
maturation could possess under physiological settings, providing
the basis for a chronic permissive environment for HIV-1
infection.
Maturation Also Enhances Presentation Skills
Why would mDCs accumulate viral particles instead of degrade
them? This paradoxical retention mechanism could in fact aid
immunological surveillance, allowing mDCs to have a source of
antigen to present to T cells in the absence of surrounding virus,
sustaining immune responses for prolonged periods. Intriguingly
enough, DCs have an inherent mechanism to control endosomal
acidification to preserve antigen cross-presentation over time [43].
We hypothesize that HIV-1 could be exploiting this preexisting
cellular pathway of antigen uptake and retention inherent to
mDCs, favoring and enhancing viral trans-infection of CD4
+ T
cells. If this is indeed the case, mDC viral uptake would not rely on
the recognition of specific viral proteins, but depend on more
ubiquitous signals.
Interestingly, we have recently identified an HIV gp120-
independent mechanism of viral binding and endocytosis that is
upregulated upon DC maturation [17], further supporting distinct
works that have demonstrated that DC-SIGN is not responsible
for HIV-1 binding to all DC subsets [21,44–53], and clearly
highlighting that additional HIV-1 binding molecules remain to be
identified.
Furthermore, several lines of evidence suggest that viral
envelope–independent capture of HIV by DCs can allow antigen
presentation and induce cytotoxic and humoral immune respons-
es. It has been previously shown that DCs can endocytose viral-like
particles (VLPs) and induce immune responses through an
endosome-to-cytosol cross-presentation pathway [54]. These VLPs
do not have the envelope glycoprotein, meaning that the uptake
mechanism could be the same as the one we have shown for virus
lacking the envelope glycoprotein [17]. In iDCs, HIV envelope
and DC-SIGN-dispensable pathways account for about 50% of
the antigen presentation through MHC-II molecules [12]. DCs
are also able to capture envelope-pseudotyped HIV Gag VLPs
through a DC-SIGN-independent pathway, activating autologous
naı ¨ve CD4
+ T cells that are then able to induce primary and
secondary responses in an ex vivo immunization assay [55].
Overall, these findings reinforce the idea that envelope-indepen-
dent capture pathways allow viral antigen presentation, thus
favoring immune responses.
The Role of Exosomes during Antigen
Presentation
Although the current view of DC functionality has iDCs
encountering an antigen in the periphery and carrying it to
lymphoid organs, DCs migrating from the periphery may not
always be the ones that present the captured antigen in the lymph
nodes. Rather, migrating DCs may transfer their captured
antigens to other DCs for presentation. The transfer could occur
either by the phagocytosis of antigen-loaded DC fragments by
another DC [56] or by the release of antigen-bearing vesicles
termed exosomes [57]. During periods of pathogen invasion, these
exosomes could act as real couriers, increasing the number of DCs
bearing a particular epitope, thus amplifying the initiation of
primary adaptive immune responses [58].
Interestingly, as it happens with viral particles, exosomes are
also internalized and stored in endocytic compartments by DCs, a
prerequisite needed to induce different immune responses.
Notably, exosomes do not induce naı ¨ve T cell proliferation in
vitro unless mDCs are also present, indicating that exosomes do
not overcome the need for a competent antigen-presenting cell to
stimulate T cells. Exosomes from cultured DCs loaded with
tumor-derived epitopes on MHC-I molecules are able to stimulate
cytotoxic T lymphocyte–mediated anti-tumor responses in vivo
[59]. Moreover, it has been demonstrated that tumor cells secrete
exosomes carrying tumor antigens, which, after transfer to DCs,
also mediate CD8
+ T cell–dependent anti-tumor effects [60].
Therefore, distinct studies have shown that exosomes carrying
tumor epitopes provide a source of antigen for cross-presentation
by DCs.
In addition, exosomes are also able to stimulate antigen-specific
naı ¨ve CD4
+ T cell responses in vivo [58,61]. This stimulation can
take place either by reprocessing the antigens contained in the
captured exosomes or by the direct presentation of previously
processed functional epitope–MHC complexes exposed in the
exosome surface [58,61]. These alternative pathways were
characterized when it was observed that mDC populations could
be devoid of MHC-II molecules and still stimulate CD4
+ T cells,
because MHC-II molecules were already present on the exosomes
[61].
In summary, distinct studies have shown that exosomes can be
internalized in DCs, allowing final antigen presentation in the
absence of lytic degradation. We suggest that HIV and other
retroviruses could be exploiting this exosome antigen dissemi-
nation pathway intrinsic to mDCs, allowing the final trans-
infection of CD4
+ T cells (Figure 3). In particular, HIV could be
hijacking a pathway that exosomes produced by antigen-
PLoS Pathogens | www.plospathogens.org 4 March 2010 | Volume 6 | Issue 3 | e1000740Figure 3. HIV can exploit a preexisting exosome trans-dissemination pathway intrinsic to mDCs, allowing the final trans-infection of
CD4
+ T cells. (A) Exosomes can transfer antigens from infected, tumoral, or antigen-presenting cells to mDCs, increasing the number of DCs bearing
a particular antigen and amplifying the initiation of primary adaptive immune responses through the MHC-II pathway, cross-presentation, or the
release of intact exosomes, a mechanism described here as trans-dissemination. (B) HIV gains access into mDCs by hijacking this exosome trans-
dissemination pathway, thus allowing the final trans-infection of CD4
+ T cells. Adapted from [63]  The American Society of Hematology.
doi:10.1371/journal.ppat.1000740.g003
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the indirect activation of CD4
+ T cells by presenting functional
epitope–MHC-II complexes through a trans-dissemination mech-
anism [58,61]. Our data supports the Trojan exosome
hypothesis that proposes that retroviruses take advantage of a
cell-encoded intercellular vesicle traffic and exosome exchange
pathway, moving between cells in the absence of fusion events
[62,63].
Are Trojan Exosomes Riding the Trojan Horse?
Upon maturation, DCs capture large amounts of HIV-1, HIV-
Gag VLPs, and Jurkat-derived exosomes, accumulating these
particles in the same intracellular compartment (Figure 4) that
stains for tetraspanins such as CD81, is characteristic of multive-
sicular bodies, and is devoid of LAMP-1 lysosomic markers [63], as
previously reported for HIV-1 [64,65]. These data are in agreement
Figure 4. Capture and transfer of HIV-1 particles by mDCs converges with the exosome-dissemination pathway. (A) Binding. Electron
microscopy images of mDCs simultaneously pulsed with HIVNL43 and Jurkat-derived exosomes. Particles displaying viral morphology (with an electro-
dense core; green arrows) or exosome morphology (with lighter core; red arrows) accumulated in the same area of the membrane. (B) Capture. Left.
Electron microscopy as in (A), showing HIVNL43 and Jurkat-derived exosome accumulation within the same vesicles. Middle. Confocal images of a
section of an mDC exposed to HIVvpr-eGFP/NL43 and Jurkat-derived exosomes labeled with DiI for 4 h and stained with DAPI. Top images show the
mDC, where the red and green fluorescence merged with DAPI either with or without the bright field cellular shape are presented. Bottom images
show magnification of vesicles containing these particles where individual green and red fluorescence and the combination of both are depicted.
Right. Confocal microscopy analysis of an mDC pulsed simultaneously with HIV Gag-eGFP VLPs and Jurkat-derived exosomes labeled with DiI and
then stained with DAPI. Composition of a series of x-y sections of an mDC collected through part of the cell nucleus and projected onto a two-
dimensional plane to show the x-z plane (bottom) and the y-z plane (right). (C) Transfer. Infectious-like synapses could also be observed in co-
cultures where mDCs were previously pulsed either with HIV Gag-eGFP VLPs (Top) or Jurkat-derived exosomes labeled with DiI (Bottom),
extensively washed, and then allowed to interact with Jurkat CD4
+ T cells. Images shown, from left to right, depict the red and green fluorescence
channels merged with DAPI, the bright field cellular shape, and the combination of both.
doi:10.1371/journal.ppat.1000740.g004
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envelope glycoprotein in mDCs and mature myeloid DCs [17].
Therefore, if exosomes use the same trafficking pathway in
mDCs as HIV, the receptors dragged from the membrane of
infected cells during viral budding that ultimately lead to viral
capture should also be present in the membrane of exosomes.
Interestingly, both exosomes and HIV can bud from particular
cholesterol-enriched microdomains in the T cell plasma mem-
brane [66–68], sharing glycosphingolipids and tetraspanin pro-
teins previously used as bona fide lipid raft markers [64,69,70].
These similarities in composition and size are a strong argument
for the Trojan exosome hypothesis, which suggests that retrovi-
ruses are, at their most fundamental level, exosomes [62].
We have further confirmed the existence of a common entry
mechanism in mDCs by observing direct competition between
different particles (HIV-1, HIV-Gag VLPs, MLV-Gag VLPs, and
exosomes) derived from similar cholesterol-enriched membrane
microdomains, which could not be inhibited by viral-size
carboxylated beads or pronase-treated vesicular stomatitis virus
particles budding from non-raft membrane locations [71].
Therefore, we consider that budding from lipid raft domains is
essential to include specific mDC recognition determinants that
allow viral and exosome capture [63].
Interestingly, a previous study revealed an association between
endocytosed HIV-1 particles and intraluminal vesicle-containing
compartments within iDCs [72]. However, the mechanism we
propose differs from this previous paper in two fundamental
aspects. First, the earlier work focuses on iDCs, and second, in
their case, virus was endocytosed into the compartment where
iDCs typically produce exosomes by reverse budding, thus
contrasting with the gather mechanism of exosome and HIV
uptake that we propose for mDCs. However, our findings concur
because HIV-1 particles captured by iDCs were exocytosed in
association with exosomes and could mediate trans-infection of
CD4
+ T cells [72]. Analogously, we found that mDC capture of
HIV-1, VLPs, and exosomes allowed efficient transmission of
captured particles to target T cells (Figure 4) [63].
The Role of Glycosphingolipids during Capture
Our data also revealed that internalization of HIV-1, VLPs, or
exosomes could not be abrogated with an effective protease
pretreatment of either of these particles or mDCs [63].
Nevertheless, this observation does not exclude the potential role
of proteins during viral or exosome capture, and might just reflect
that the molecular determinants involved in capture were not fully
processed by the proteases employed. However, treatment of
virus-, VLP-, or exosome-producing cells with inhibitors of
sphingolipid biosynthesis (such as fumonisin B1 and N-butyl-
DNJ) extensively reduced particle entry into mDCs without
interfering with their net release from producer cells. Although it
has been previously shown that certain ceramide inhibitors
diminish the infectivity of released HIV-1 particles after treatment
of virus-producer cells [73] and can block HCV replication in vitro
[74], at the viral input used in our study differences in infectivity
were moderate. Moreover, treatment with a different agent that
specifically blocks glycosphingolipid biosynthesis (N-butyl-DNJ)
did not affect viral infectivity at all, while inhibiting viral mDC
capture. Therefore, our findings establish a critical role for
glycosphingolipids during mDC binding and endocytosis of
particles derived from cholesterol-enriched domains such as HIV
and exosomes [63,75]. These data could imply a direct interaction
of the glycosphingolipids with the plasma membrane of mDCs.
Alternatively, the glycosphingolipids could maintain the structural
entities required for viral and exosome binding to mDCs, allowing
the interaction of pronase-resistant proteins with the mDC
membrane surface. Further studies will help to clarify which of
the two models our data support actually accounts for particle
endocytosis.
Concluding Remarks
The capture of retroviruses and exosomes is upregulated upon
DC maturation, leading internalized particles into the same
CD81
+ intracellular compartment and allowing efficient transmis-
sion to CD4
+T cells. This novel capture pathway, where
retroviruses and exosomes converge, has clear implications for
the design of effective HIV therapeutic vaccines. Although mDCs
pulsed with inactivated virus could stimulate specific CD8
+ T cell
immune responses in infected patients, as reviewed in [76], these
injected mDCs could also mediate trans-infection of new CD4
+ T
target cells, amplifying viral dissemination. Therefore, the safety of
these strategies should be carefully evaluated, and preferentially
explored in patients with undetectable viral load. Regarding
prophylactic HIV vaccines, the proposed exosomal origin of
retrovirus predicts that HIV poses an unsolvable paradox for
adaptive immune responses [62]. Further work should address the
specific differences between retroviral particles and exosomes to
overcome these difficulties.
Taken as a whole, our results suggest that mDCs, which have a
greater ability than iDCs to transmit the virus to target cells and
interact continuously with CD4
+ T cells at the lymph nodes—the
key site of viral replication—could play a prominent role in
augmenting viral dissemination. Underscoring the molecular
determinants of this highly efficient viral capture process, where
retroviruses mimic exosomes to evade the host immune system,
could lead to new therapeutic strategies for infectious diseases
caused by retroviruses, such as HIV-1, and T lymphotropic agents
such as HTLV-1. Furthermore, this knowledge can help in the
design of safer candidates for use in a DC-based vaccine.
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